Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Urine Osteoprotegerin and Monocyte Chemoattractant Protein-1 in Lupus Nephritis

ADNAN N. KIANI, KRISTEN JOHNSON, CATHERINE CHEN, EDWARD DIEHL, HUAIZHONG HU, GANESH VASUDEVAN, SUKHMINDER SINGH, LAURENCE S. MAGDER, STUART J. KNECHTLE and MICHELLE PETRI
The Journal of Rheumatology October 2009, 36 (10) 2224-2230; DOI: https://doi.org/10.3899/jrheum.081112
ADNAN N. KIANI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KRISTEN JOHNSON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CATHERINE CHEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EDWARD DIEHL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HUAIZHONG HU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GANESH VASUDEVAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUKHMINDER SINGH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LAURENCE S. MAGDER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STUART J. KNECHTLE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHELLE PETRI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mpetri{at}jhmi.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Abstract

Objective. Renal biopsy is the “gold standard” to determine renal activity in systemic lupus erythematosus (SLE), but it is expensive, invasive, and carries risk. Osteoprotegerin (OPG) is produced by the heart, lungs, kidney, and bone. Monocyte chemoattractant protein-1 (MCP-1), a chemotactic cytokine, is involved in the progression of glomerular and tubulointerstitial injury. We investigated both urine OPG and MCP-1 as potential biomarkers for lupus nephritis.

Methods. Our subjects, 87 patients with SLE (88% women; 48% African American, 41% Caucasian, 11% other), mean age 44 years, were followed monthly to quarterly. Urinary OPG (pg/ml) and MCP-1 (pg/ml) were measured (Luminex MAP bead assay).

Results. OPG concentrations were strongly associated with global disease activity and with both renal activity on a visual analog scale (VAS) (p = 0.0006) and renal disease activity descriptors of the SELENA SLEDAI, including hematuria (p = 0.001) and a positive anti-dsDNA (p = 0.013). MCP-1 was also associated with the renal VAS (p = 0.032), renal disease activity descriptors of SELENA SLEDAI, including hematuria (p = 0.027), and with a positive anti-dsDNA (p = 0.016). We also examined the relationship between the biomarkers and having a urine protein to creatinine ratio (pr/cr) ≥ 0.5. Among patients with medium or high OPG, 46% had urine pr/cr ≥ 0.5, compared to only 23% among those with low OPG (p = 0.032). The 2 biomarkers were strongly correlated with each other (Spearman correlation coefficient 0.77, p < 0.0001).

Conclusion. The lack of availability of urine biomarkers has hampered development of new therapies for lupus nephritis. Urine MCP-1 and OPG were both associated with measures of lupus renal disease activity. Medium or high levels of OPG were predictive of a urine protein/creatinine ratio of ≥ 0.5. Further study, including longitudinal assessment and correlation with concurrent renal biopsies, is necessary before this assay can be used in the routine clinic setting.

  • BIOMARKERS
  • LUPUS NEPHRITIS
  • OSTEOPROTEGERIN
  • MONOCYTE CHEMOATTRACTANT PROTEIN-1

Lupus nephritis occurs in over 50% of patients with systemic lupus erythematosus (SLE). It is both more common and more severe in non-Caucasian patients1–3. Although essential in the diagnosis of lupus nephritis, repeated renal biopsy to determine the International Society of Nephrology (ISN) class and activity score is not practical, due to cost, invasiveness, and risk. In addition, lupus nephritis can fluctuate over time, even changing ISN class. Although urine sediment and quantification of urine protein can be helpful, they do not distinguish among ISN classes. Studies of murine lupus have shown the importance of cytokines and chemokines, such as interleukin 4 (IL-4), in the pathogenesis of glomerular inflammation4. However, to be clinically practical, biomarkers of lupus nephritis would need to be measured in the urine, ideally by protein concentration, rather than by mRNA expression.

Osteoprotegerin (OPG), a member of the tumor necrosis factor (TNF) receptor family, has been identified as a regulator of bone resorption5. It has been demonstrated that OPG is produced by a variety of organs and tissues, including the cardiovascular system (heart, arteries, veins), lung, kidney, and immune tissues, as well as bone5,6. The expression and production of OPG are regulated by various cytokines and hormones7. Human microvascular endothelial cells (HMVEC) express transcripts for OPG, and tumor necrosis factor-α and IL-1α increase OPG expression 5- to 40-fold in HMVEC8. Increased plasma concentrations of OPG have been found in patients with diabetes mellitus9–11 and have been associated with diabetic microvascular manifestations11. It is hypothesized that kidney excretion plays an important role in the clearance of OPG. Thus, OPG concentration in the urine might rise in a lupus nephritis flare, because of the increased production and excretion from inflamed microvascular endothelial cells in the kidney.

Monocyte chemoattractant protein-1 (MCP-1), a chemotactic cytokine, plays an important role in the progression of glomerular and tubulointerstitial injuries in experimental and human glomerulonephritides12–14. A variety of cell types including glomerular endothelial, mesangial, and tubular epithelial cells may produce MCP-1 in response to inflammatory signals, such as cytokines (IL-1, TNF-α) and immune complexes15–17. MCP-1 has been found at high levels in the urine of patients with active lupus nephritis18. Evidence in human and animal studies highlights the importance of MCP-1 for renal injury in lupus nephritis19,20. In human SLE, urinary levels of MCP-1 are markedly elevated in patients with lupus nephritis, and the presence of MCP-1 in urine reflects its intrarenal expression21–23. A polymorphism in the MCP-1 gene regulatory region influences MCP-1 expression24. Urine MCP-1 levels have been shown to decline with treatment of nephritis25. MCP-1 levels are also affected by the presence or absence of diabetes mellitus26.

Based on preliminary screening that suggested that OPG and MCP-1 were the 2 most promising urine biomarkers, we studied both in a longitudinal study of patients with SLE.

MATERIALS AND METHODS

Eighty-seven patients participating in the Hopkins Lupus Cohort, a prospective longitudinal study of lupus activity and outcomes, were studied. This included 55 patients with lupus nephritis, 12 SLE patients with diabetes mellitus, 10 SLE patients receiving angiotensin-converting enzyme (ACE) inhibitors, 7 SLE patients receiving angiotensin receptor blockers, and 3 patients with active lupus. The cohort protocol required a visit every 3 months, but patients were seen more often based on disease activity. Urine samples were collected at each visit. At each visit, disease activity indices [physician’s global assessment; Safety of Estrogens in Lupus Erythematosus: National Assessment – SLE Disease Activity Index (SELENA SLEDAI)27; and renal activity on a 0 to 3 visual analog scale (VAS)]28 were calculated. Vital signs (weight, blood pressure), laboratory tests (complete blood count, platelets, erythrocyte sedimentation rate, creatinine, cholesterol, C3, C4, anti-dsDNA, anticardiolipin, lupus anticoagulant by Russell’s viper venom time, urinalysis, urine protein:creatinine ratio), and treatment (prednisone, immunosuppressives, hydroxychloroquine, ACE inhibitor and dose, angiotensin receptor blocker and dose) were recorded.

The study was approved by the Johns Hopkins University School of Medicine Institutional Review Board. All patients gave informed consent.

Quantifying renal disease activity

To quantify renal disease activity, we also used the Systemic Lupus International Cooperating Clinics renal activity score29, derived from a regression analysis using the physician rating of renal activity as the “gold standard.” It is calculated as follows: proteinuria 0.5 to 1 g/day (3 points), proteinuria 1 to 3 g/day (5 points), proteinuria > 3 g/day (11 points), urine red blood cells ≥ 5/hpf (3 points), and urine white blood cells ≥ 5/hpf (1 point).

Urine collection, preparation, and biomarker measurement

OPG and MCP-1 were measured using the Renovar non-washing biplex assay (Renovar Inc., Madison, WI, USA); results were reported as pg/ml. Urine “clean catch-midstream” samples of 25–50 ml were collected into an appropriate sterile container, and placed on ice or refrigerated at 4°C within 1 h of collection. Aliquots and the remaining urine sample in the centrifuge tube were frozen at −80°C and batched for shipment to Renovar, Inc.

At Renovar, samples were centrifuged at 1500 rpm for 10 min. The supernatant of each sample was aliquoted and stored at −80°C until use. Multi-analyte profiling (xMAP) technology (Luminex, Austin, TX, USA) was used for simultaneous quantification of urinary OPG and MCP-1. The capture antibodies directed respectively at OPG and MCP-1 were separately preconjugated to their corresponding particles following the Luminex coupling protocol. Quantification of OPG and MCP-1 was conducted in 96-well flat-bottom plates. Twenty-five microliters of mixed OPG and MCP-1 standards or urinary samples were added to wells containing 25 μl of assay buffer and 25 μl of precoated particles, and incubated on a 3-D rotator (Labline Instrument Inc., Melrose Park, IL, USA) at 60 rounds/min at room temperature (RT) for 60 min. Mixed biotin-labeled detection antibodies directed at OPG and MCP-1 were then added and incubated on the rotator at 60 rounds/min at RT for 60 min before the addition of streptavidin-PE. After an additional 30 min incubation on the rotator at 60 rounds/min at RT, data acquisition and analysis were performed on a Luminex 100 IS analyzer. Concentrations of OPG and MCP-1 in urine samples were determined by referring the mean fluorescence intensity of the samples to the respective standard curves. The detection limit (or the assay sensitivity) was 5 pg/ml, and the inter- and intra-assay variability was < 10% for both MCP-1 and OPG.

Statistical methods

To adjust for the variable urine concentration, we normalized our measures of MCP-1 and OPG by dividing by the urine creatinine concentration. Because the resulting distributions of MCP-1 and OPG were markedly skewed, we transformed each variable by taking the loge(variable + 1) prior to calculating means and performing inference. To assess the relationship between various types of SLE activity and the biomarker levels, we compared visits with and without the activity measure with respect to the means of the log-transformed MCP-1 and OPG. Statistical inferences regarding associations with biomarkers were based on models including a random effect for the patient in order to account for the correlation between repeated observations from the same patient. To assess whether changes in the biomarker were associated with changes in the urine protein to creatinine (pr/cr) ratio, we calculated the person-specific correlation coefficients between the biomarkers and urine pr/cr ratio, and determined the proportion of these correlation coefficients that were positive. To determine whether these proportions were significantly greater than 0.5, we used a sign test.

In additional analyses, we explored whether combining urine OPG and MCP-1 resulted in better prediction of urine pr/cr than either test alone. Due to the reported relationship among the biomarkers and diabetes mellitus, ACE inhibitors, and angiotensin receptor blockers, we also redid all the analyses after excluding SLE patients with these conditions/medications.

RESULTS

Data were obtained on 87 patients (88% women) with SLE. MCP-1 and OPG were measured at 1–5 visits per patient over the course of a 6-month period for a total of 184 visits. The ethnic breakdown was African American (48%), Caucasian (41%), Asian (5%), Hispanic (3%), and other ethnicity (2%). The mean age was 44 years. Cumulative clinical manifestations included ANA positivity 95%, immunologic disorder 89%, arthritis 71%, renal disorder 70%, serositis 54%, malar rash 51%, photosensitivity 50%, oral ulcers 44%, discoid rash 23%, and neurological disorder 15%.

Figure 1 illustrates the association between the proposed assays and the urine pr/cr ratio (after normalizing for urine creatinine). These plots are based on 154 visits from the 79 patients in whom the urine pr/cr ratio was measured. Spearman correlation coefficients between the urine pr/cr ratio and the log biomarkers were 0.25 and 0.34 for MCP-1 and OPG, respectively.

Urine protein plotted against the log of urine monocyte chemoattractant protein-1 (MCP-1) and osteoprotegerin (OPG) normalized by urine creatinine.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Urine protein plotted against the log of urine monocyte chemoattractant protein-1 (MCP-1) and osteoprotegerin (OPG) normalized by urine creatinine.

Figure 2 illustrates the association between the normalized biomarkers and the renal activity score. Spearman correlation coefficients between the renal activity score and the log biomarkers were 0.33 and 0.46 for MCP-1 and OPG, respectively. Although the p values were significant, the association was not very strong.

Renal disease activity score plotted against the log of urine monocyte chemoattractant protein-1 (MCP-1) and osteoprotegerin (OPG) normalized by urine creatinine.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Renal disease activity score plotted against the log of urine monocyte chemoattractant protein-1 (MCP-1) and osteoprotegerin (OPG) normalized by urine creatinine.

Table 1 shows the association between the biomarkers and various clinical conditions. OPG levels were strongly associated with physician’s global estimate of disease activity and the renal VAS. OPG was also associated with hematuria (p = 0.001), urine pr/cr ratio (p = 0.032), and the presence of anti-dsDNA (p = 0.013). MCP-1 was also associated with the renal VAS (p = 0.032), hematuria (p = 0.027), and presence of anti-dsDNA (p = 0.016) (Table 1).

View this table:
  • View inline
  • View popup
Table 1.

Mean (SD) log-transformed and normalized (by urine creatinine) OPG and MCP-1, by clinical variables at each visit.

Table 2 shows the relationship between the biomarkers and having a urine pr/cr ≥ 0.5. Among those with medium or high OPG, 46% had urine pr/cr ≥ 0.5, compared to only 23% of those with low OPG (p = 0.032).

View this table:
  • View inline
  • View popup
Table 2.

Proportion (%) of patient visits with urine protein/creatinine ≥ 0.5 in subgroups defined by level of MCP-1 and OPG (normalized to urine creatinine).

We next studied whether, within a patient, there was an association between changes in the new assays and changes in the urine pr/cr ratio. This analysis included 51 patients with 2 or more measures of MCP-1 and OPG. The “within-person” correlation of urine pr/cr and MCP-1 was positive for 30/51 (p = 0.26, sign test). For OPG, 34/51 were positive (p = 0.024, sign test).

Table 3 shows the sensitivity, specificity, and positive and negative predictive values of various rules defined based on the biomarkers for identifying patients with high levels of renal activity (as defined by renal activity score ≥ 4). The area under the receiver-operation characteristic (ROC) curve for OPG is 0.73. The area under the ROC curve for MCP-1 is 0.66. The area under the ROC curve for a model with both OPG and MCP-1 is 0.74.

View this table:
  • View inline
  • View popup
Table 3.

Sensitivity, specificity, positive and negative predictive values of various rules for identifying patients with renal activity score ≥ 4 points based on MCP-1 and OPG.

Fourteen patients had a renal biopsy within 1 year of the biomarker measurement. Table 4 shows the relationship between the biomarkers and the biopsy results.

View this table:
  • View inline
  • View popup
Table 4.

Analysis of renal biopsies by International Society of Nephrology class within 1 year.

Combining the 2 biomarkers also yielded interesting results. The 2 biomarkers were strongly correlated with each other (Spearman correlation coefficient 0.77, p < 0.0001). As a result, the 2 together did not have a substantially stronger correlation with disease activity or urine pr/cr ratio than one alone. As noted, the Spearman correlation coefficient between urine pr/cr and OPG was found to be 0.34. Adding MCP-1 to the model did not improve the correlation (joint correlation coefficient, based on ranked data, 0.34). Similarly, the correlation coefficient between OPG and the renal activity score (0.46) and adding MCP-1 to the model resulted in a joint correlation coefficient of the same magnitude (0.46).

There was not a strong relationship between the biomarkers and either diabetes mellitus or use of ACE inhibitor or angiotensin receptor blocker (Table 1). When we redid the analyses described above after excluding patients with diabetes mellitus and those taking an ACE inhibitor or angiotensin receptor blocker, all the results were qualitatively similar to those reported above.

DISCUSSION

Lupus nephritis occurs in over 50% of patients with SLE and is frequently associated with a poor longterm prognosis. The glomerular filtration apparatus and proximal tubular absorption of ultra-filtered proteins all determine the protein/peptide composition of urine. A diseased kidney may lead to the generation of certain proteins in the urine, either in an intact form or more likely as peptide fragments. In either case, identifying these proteins/peptides would help identify the pathologic process and could lead in the future to primary or secondary preventive measures. Serum complement levels (C3 and C4) and anti-double-stranded DNA are most commonly used to evaluate lupus renal flares, but the results are controversial30–32. Renal biopsy, although the gold standard, carries its own risks. There is an immediate need of noninvasive markers that associate with renal activity and carry minimal risk to the patient.

In one previous study, OPG levels decreased significantly to normal 3 months after successful renal transplant (from 10.05 ± 4.77 pmol/l to 4.59 ± 2.26 pmol/l)33. In human SLE, urinary levels of MCP-1 were markedly elevated in patients with lupus nephritis and the presence of MCP-1 in urine reflected intrarenal expression21–23. Other studies have shown a decrease in urine MCP-1 levels with treatment34–38.

Our study is the first to show OPG to be a significant associate of renal activity in SLE patients. OPG levels were strongly associated with the renal VAS, urine pr/cr ratio, hematuria, and the presence of anti-dsDNA. Medium or high levels of OPG were associated with a urine pr/cr ratio of ≥ 0.5. Our study verifies previous reports of increased urine MCP-1 in SLE34,36,39. In our study, MCP-1 was also associated with renal disease activity descriptors, including hematuria, and with a positive anti-dsDNA.

These preliminary results demonstrate the potential of both these assays, which might have utility in the identification of patients with lupus having continuing subclinical renal activity, or conversely, in identifying patients who do not need a kidney biopsy. Since renal pathology can change over time, further study with larger numbers of SLE patients, including longitudinal assessment and correlation with concurrent renal biopsies, is necessary before these assays can be used in the routine clinic setting. We also did not have sufficient numbers to distinguish between the presence and absence of a lupus nephritis flare; these are the limitations of our study.

This was the largest study to date of urinary OPG and MCP-1 in SLE, and highlights the importance of and need for urine biomarkers in SLE. The lack of availability of urine biomarkers has hampered development of new therapies for lupus nephritis. Validation of these urine biomarkers with concurrent renal biopsies might allow them to be used as surrogate outcomes in future lupus nephritis trials and in routine SLE care.

Footnotes

  • The Hopkins Lupus Cohort is supported by a grant from the National Institutes of Health (NIH AR43727). This publication was also made possible by grant no. UL1 RR 025005 from the National Center for Research Resources (NCRR).

    • Accepted for publication May 19, 2009.

REFERENCES

  1. 1.↵
    1. Austin HA,
    2. Boumpas DT,
    3. Vaughan EM,
    4. Balow JE
    . High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995;10:1620–8.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Dooley MA,
    2. Hogan S,
    3. Jennette C,
    4. Falk R
    . Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997;51:1188–95.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Bastian HM,
    2. Alarcon GS,
    3. Roseman JM,
    4. et al.
    Systemic lupus erythematosus in a multi-ethnic US cohort (LUMINA) XLII: Factors predictive of new or worsening proteinuria. Rheumatology 2007;46:683–9.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Singh RR,
    2. Saxena V,
    3. Zang S,
    4. Li L,
    5. Finkelman FD,
    6. Witte DP
    . Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 2003;170:4818–25.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Simonet WS,
    2. Lacey DL,
    3. Dunstan CR
    . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–19.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Yun TJ,
    2. Chaudhary PM,
    3. Shu GL
    . OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 1998;161:6113–21.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Hofbauer LC,
    2. Khosla S,
    3. Dunstan CR
    . The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2–12.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Collin-Osdoby P,
    2. Rothe L,
    3. Anderson F
    . Receptor activator of NF-kB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis J Biol Chem 2001;276:20659–72.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Browner WS,
    2. Lui LY,
    3. Cummings SR
    . Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures and mortality in elderly women. J Clin Endocrinol Metabol 2001;86:631–7.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Schoppet M,
    2. Sattler AM,
    3. Schaefer JR,
    4. Herzum M,
    5. Maisch B,
    6. Hofbauer LC
    . Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metabol 2003;88:1024–8.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Knudsen ST,
    2. Foss CH,
    3. Poulsen PL,
    4. Andersen NH,
    5. Mogensen CE,
    6. Rasmussen LM
    . Increased plasma concentrations of OPG in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003;149:39–42.
    OpenUrlAbstract
  12. 12.↵
    1. Stahl RA,
    2. Thaiss F,
    3. Disser M,
    4. Hora K,
    5. Schlondorff D
    . Increased expression of MCP-1 in anti-thymocyte antibody-induced glomerulonephritis. Kidney Int 1993;44:1036–47.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Rovin BH,
    2. Doe N,
    3. Tan LC
    . MCP-1 levels in patients with glomerular disease. Am J Kidney Dis 1996;27:640–6.
    OpenUrlPubMed
  14. 14.↵
    1. Saitoh A,
    2. Suzuki Y,
    3. Takeda M,
    4. Kubota K,
    5. Itoh K,
    6. Tomino Y
    . Urinary levels of MCP-1 and disease activity in patients with IgA nephropathy. Clin Lab Anal 1998;12:10–5.
    OpenUrl
  15. 15.↵
    1. Baggiolini M,
    2. Dewald B,
    3. Moser B
    . IL-8 and related chemotactic cytokines — CXC and CC chemokines. Adv Immunol 1994;55:97–179.
    OpenUrlPubMed
  16. 16.↵
    1. Sica A,
    2. Wang JM,
    3. Colotta F
    . MCP-1 and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. J Immunol 1990;144:3034–8.
    OpenUrlAbstract
  17. 17.↵
    1. Satriano JA,
    2. Hora K,
    3. Shan Z,
    4. Stanley ER,
    5. Mori T
    . Regulation of MCP-1 and macrophage colony stimulating factor-1 by IFN-gamma, tumor necrosis factor-alpha, IgG aggregates, and cAMP in mouse mesangial cells. J Immunol 1993;150:1971–8.
    OpenUrlAbstract
  18. 18.↵
    1. Brown KS,
    2. Nackos E,
    3. Morthala S,
    4. Von Feldt JM
    . Monocyte chemoattractant protein-1: Plasma concentrations and A(−2518)G promoter polymorphism of its gene in systemic lupus erythematosus. J Rheumatol 2007;34:740–6.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Kelley VR,
    2. Rovin BH
    . Chemokines: therapeutic targets for autoimmune and inflammatory renal disease. Springer Semin Immunopathol 2003;24:411–21.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Rovin BH,
    2. Phan LT
    . Chemotactic factors and renal inflammation. Am J Kidney Dis 1998;31:1064–84.
    OpenUrl
  21. 21.↵
    1. Wada T,
    2. Yokoyama H,
    3. Su SB,
    4. Iwano M,
    5. Dohi K
    . Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996;49:761–7.
    OpenUrlPubMed
  22. 22.↵
    1. Tucci M,
    2. Barnes EV,
    3. Sobel ES,
    4. Croker BP,
    5. Segal MS
    . Strong association of a functional polymorphism in the MCP-1 promoter gene with LN. Arthritis Rheum 2004;50:1842–9.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Noris M,
    2. Bernasconi S,
    3. Sozzani S,
    4. Gotti E,
    5. Remuzzi G
    . MCP-1 is excreted in excessive amounts in the urine of patients with LN. Lab Invest 1995;73:804–9.
    OpenUrlPubMed
  24. 24.↵
    1. Rovin BH,
    2. Lu L,
    3. Saxena R
    . A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999;259:344–8.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Li Y,
    2. Tucci M,
    3. Narain S,
    4. et al.
    Urinary biomarkers in lupus nephritis. Autoimmun Rev 2006;5:383–8.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Tesch GH
    . MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008;294:697–701.
    OpenUrlCrossRef
  27. 27.↵
    1. Petri M,
    2. Kim MY,
    3. Kalunian KC,
    4. et al.
    OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550–8.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Petri M,
    2. Hellmann D,
    3. Hochberg M
    . Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992;19:53–9.
    OpenUrlPubMed
  29. 29.↵
    1. Petri M,
    2. Kasitanon N,
    3. Lee SS,
    4. Magder LS,
    5. Link K
    . Systemic Lupus Erythematosus Clinical Studies Systemic lupus International Collaborating Clinics renal activity/response exercise: Development of a renal activity score and renal response index. Arthritis Rheum 2008;58:1784–8 (erratum Arthritis Rheum 2008;58:2823).
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Coremans IEM,
    2. Spronk PE,
    3. Bootsma H
    . Changes in antibodies to C1q predict renal relapse in system lupus erythematosus. Am J Kidney Dis 1995;26:595–601.
    OpenUrlPubMed
  31. 31.↵
    1. Ho A,
    2. Barr SG,
    3. Magder LS
    . A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2350–67.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Ho A,
    2. Magder LS,
    3. Barr SG
    . Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2342–9.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Bargnoux AS,
    2. Dupuy AM,
    3. Garrigue V,
    4. Deleuze S,
    5. Cristol JP,
    6. Mourad G
    . Renal transplantation decreases OPG levels. Transplant Proc 2006;38:2317–8.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Wada T,
    2. Yokoyama H,
    3. Su S,
    4. et al.
    Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996;49:761–7.
    OpenUrlPubMed
  35. 35.↵
    1. Wada T,
    2. Yokoyama H,
    3. Tomosugi N,
    4. et al.
    Detection of urinary interleukin-8 in glomerular diseases. Kidney Int 1994;46:455–60.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Noris M,
    2. Bernasconi S,
    3. Casiraghi F,
    4. et al.
    Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995;73:804–9.
    OpenUrlPubMed
  37. 37.↵
    1. Tesar V,
    2. Masek Z,
    3. Rychlik I,
    4. et al.
    Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol Dial Transplant 1998;13:1662–7.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Tsai C-Y,
    2. Wu T-H,
    3. Yu C-L,
    4. Lu J-Y,
    5. Tsai Y-Y
    . Increased excretions of ß2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in the urine of patients with active lupus nephritis. Nephron 2000;85:207–14.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Rovin BH,
    2. Song H,
    3. Birmingham DJ,
    4. Hebert LA,
    5. Yu CY,
    6. Nagaraja HN
    . Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 1995;16:467–73.
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 36, Issue 10
1 Oct 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Urine Osteoprotegerin and Monocyte Chemoattractant Protein-1 in Lupus Nephritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Urine Osteoprotegerin and Monocyte Chemoattractant Protein-1 in Lupus Nephritis
ADNAN N. KIANI, KRISTEN JOHNSON, CATHERINE CHEN, EDWARD DIEHL, HUAIZHONG HU, GANESH VASUDEVAN, SUKHMINDER SINGH, LAURENCE S. MAGDER, STUART J. KNECHTLE, MICHELLE PETRI
The Journal of Rheumatology Oct 2009, 36 (10) 2224-2230; DOI: 10.3899/jrheum.081112

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Urine Osteoprotegerin and Monocyte Chemoattractant Protein-1 in Lupus Nephritis
ADNAN N. KIANI, KRISTEN JOHNSON, CATHERINE CHEN, EDWARD DIEHL, HUAIZHONG HU, GANESH VASUDEVAN, SUKHMINDER SINGH, LAURENCE S. MAGDER, STUART J. KNECHTLE, MICHELLE PETRI
The Journal of Rheumatology Oct 2009, 36 (10) 2224-2230; DOI: 10.3899/jrheum.081112
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Validation of Handheld Ultrasound Devices for Point-of-Care Use in Rheumatology: Focus on Synovitis, Doppler Activity, Erosions, and Tendon Lesions
  • Persistent Opioid Exposure in Older Adults With Rheumatic Disease: National Patterns, Disparities, and Cross-Specialty Prescribing
  • What Makes Axial Spondyloarthritis Difficult to Manage? A Qualitative Study of Patient and Rheumatologist Perspectives
Show more Article

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire